437 results about "Myocardial cell" patented technology

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention belongs to the technical field of cell electrophysiological signal recognition, and discloses a cell electrophysiological signal recognition method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining an original electrophysiological signal of a myocardial cell, mechanical data of the action of a mechanical probe and the myocardial cell, and illumination parameters of an optical imaging system, the method comprises the following steps: acquiring an original electrophysiological signal, identifying from the original electrophysiological signal to obtain a mechanical artifact signal associated with mechanical data, determining instantaneous mechanical stiffness of myocardial cells based on the mechanical artifact signal so as to identify and obtain a pulsation stage in which the myocardial cells are currently located, and calculating to obtain a photo-thermal artifact signal in the original electrophysiological signal according to the pulsation stage and illumination parameters, separating a mechanical artifact signal and a photo-thermal artifact signal from the original electrophysiological signal to obtain a real electrophysiological signal of the myocardial cell; by means of the method, the electrophysiological signal recognition accuracy of the myocardial cells is improved.

The invention relates to the field of biological extraction, substance analysis, application and effect evaluation, in particular to an extraction method of polysaccharide of an overground part of chicory, the polysaccharide and a related application and evaluation method. The method comprises the following steps: providing an extraction method of the polysaccharide of the overground part of the chicory, carrying out reflux extraction, concentration, precipitation, centrifugation, washing and freeze-drying to obtain the polysaccharide, and carrying out molecular weight distribution and monosaccharide composition analysis on the polysaccharide, and the polysaccharide has antioxidant and anti-inflammatory activity, can be used for preparing products for protecting myocardial cells and the like, and has wide application prospects. The invention also discloses a composition containing the polysaccharide and an evaluation method for comparing the myocardial protection activity of the polysaccharide at different parts of the cichorium intybus. The application achieves the technical effects of efficiently extracting the polysaccharide of the overground part of the chicory, determining the characteristics and effects of the polysaccharide, providing a basis for development of products related to cardiovascular disease prevention and treatment, and providing a method for evaluating the myocardial protection activity of the polysaccharide of different parts of the chicory.

The invention relates to the technical field of biological medicines, in particular to a polycyclic polyisopentenyl cyclopentanone compound as well as a preparation method and application thereof. The polycyclic polyisopentenyl cyclopentanone compound provided by the invention has a structural formula as shown in a formula 1; the preparation method comprises the following steps: by taking dry fruits of hypericum berry as raw materials, carrying out percolation extraction and concentration to obtain an extract, suspending the extract in water to obtain a suspension, and extracting and concentrating the suspension with petroleum ether to obtain a crude extract; the crude extract is taken and subjected to positive and negative phase silica gel column separation, MCI medium-pressure column chromatography, Sephadex LH-20 gel column chromatographic separation, high performance liquid chromatography preparation and CHIRALPAK IG chiral column resolution, and the polycyclic polyisopentenyl cyclopentanone compound is obtained. The protection activity of the compound on AC16 myocardial cell injury induced by cold ischemia is evaluated, and the compound can be used for preparing the polycyclic polyisopentenyl cyclopentanone compound. The compounds can be used as lead compounds for developing medicines for preventing and treating myocardial cold ischemia injury.

The present disclosure describes systems and methods for cell therapy. Cells (e.g., stem cells, immune cells, cardiomyocytes, etc.) may be engineered to exhibit extended half-lives as compared to control cells (e.g., non-engineered cells). The cells may be engineered to exhibit increased proliferative activity as compared to control cells. In some embodiments, immune cells may be engineered to efficiently and specifically target diseased cells (e.g., cancer cells) while control cells are insufficient or unable to target the diseased cells. In some embodiments, stem cells or differentiated cells, such as myocardial cells, may be administered to a target tissue for enhanced tissue engineering or regenerative medicine. The engineered cells disclosed herein can be engineered ex vivo, in vitro, and in some embodiments in vivo. Engineered cells prepared ex vivo or in vitro may be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumor). The engineered cell may be autologous to the subject. Alternatively, the engineered cell may also be allogeneic to the subject.

The application provides a sub-threshold heart communication method, system, device, medium and application, and belongs to the technical field of biomedical engineering. The method comprises the following steps: constructing a communication channel formed by coupling of multiple three-dimensional myocardial cell models; modulating physiological information into a sub-threshold electrical signal and injecting the signal into the channel for transmission; demodulating the signal at a receiving end to recover the information; wherein a physiological noise model is integrated in the channel to simulate a real physiological environment. The system corresponds to a transmitting end, a communication channel and a receiving end. The application adopts the sub-threshold heart communication method, system, device, medium and application, the three-dimensional myocardial cell model is used to more truly simulate a heart tissue structure, the complete communication process simulation of the sub-threshold electrical signal in a noise environment is realized for the first time, the existing research gap is filled, and an innovative technical platform is provided for research on cardiac electrophysiological mechanisms, performance optimization and evaluation of implantable medical devices such as a cardiac pacemaker.

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

This invention discloses a cardioprotective compound composition and its preparation based on improving the absorption rate of coenzyme Q10, relating to the fields of pharmaceuticals and functional foods. The core active ingredients of this composition consist of coenzyme Q10, vitamin E, and black pepper extract, with a specific mass ratio range for each. It can also be combined with pharmaceutically acceptable carriers and antioxidant synergists to prepare various oral formulations. This invention, through the construction of a ternary active component with a specific ratio, achieves in vivo synergistic effects on absorption promotion and antioxidant regeneration, solving the technical problems of low oral bioavailability and insufficient accumulation of myocardial-targeted activity in existing coenzyme Q10 preparations. It significantly improves the conversion efficiency of coenzyme Q10 into a usable active form for cardiomyocytes and can be widely applied in the preparation of drugs and functional foods for the prevention or treatment of heart diseases.

The invention discloses construction of myocardial cells differentiated from propionemia stem cells based on a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The model constructed by the invention has the metabolic phenotype of propionemia and can also be differentiated into myocardial cells. A reliable and effective experimental model is provided for research of propionemia disease related targets and screening of drugs for preventing / treating propionemia, and the method has a wide application prospect.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The application discloses application of a BLM helicase inhibitor in treating myocardial hypertrophy. The application firstly finds that the BLM helicase inhibitor ML216 can significantly inhibit cardiac hypertrophy and myocardial cell fibrosis, thereby providing a new drug for treating myocardial cell hypertrophy diseases in the field, and providing practical experimental evidence and scientific basis for treating myocardial cell hypertrophy diseases, and having a good application prospect in treating myocardial hypertrophy and / or cardiac hypertrophy.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention belongs to the field of traditional Chinese medicine chemistry and natural product separation, and particularly relates to extraction and separation of a novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol and application of the novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol in myocardial protection drugs. The compound is named as 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol, and the structural formula of the compound is shown in the description. The invention provides an extraction and separation method of the compound. The extraction and separation method mainly comprises the following steps: sequentially carrying out solvent extraction, macroporous adsorption resin enrichment, silica gel column chromatography, ODS medium-pressure column chromatography, high performance liquid chromatography separation and purification and the like on ginseng and other traditional Chinese medicine processed products and hydrolysates. The structure of the compound is determined through comprehensive analysis of a high-resolution mass spectrum (HRMS), one-dimensional nuclear magnetic resonance (1H NMR, 13C NMR) and a two-dimensional nuclear magnetic resonance spectrum (such as HSQC, HMBC, ROESY and the like), and the compound is a newly discovered dammarane type triterpene compound. Experiments show that the compound and the composition thereof have a remarkable protection effect on myocardial cell hypoxia / reoxygenation reperfusion injury, and can be used for preparing drugs for preventing or treating myocardial ischemia reperfusion injury and other related diseases.

This invention discloses the application of alismazone B acetate in the preparation of drugs for the prevention or treatment of hypertrophic cardiomyopathy and its related symptoms. This invention is the first to propose the use of alismazone B acetate (AB23a) for the prevention or treatment of hypertrophic cardiomyopathy. The invention utilizes AB23a to directly treat cardiomyocytes obtained from directed differentiation of human embryonic stem cells in vitro, finding that AB23a treatment significantly inhibits the hypertrophic phenotype of human embryonic stem cell-cardiomyocytes. Feeding mice with hereditary hypertrophic cardiomyopathy caused by gene mutations to a diet containing AB23a showed that AB23a significantly alleviated pathological myocardial hypertrophy and improved cardiac function in mice. AB23a can be used to prepare drugs against hereditary hypertrophic cardiomyopathy, providing a new approach and method for treating hypertrophic cardiomyopathy. AB23a is the most important medicinal component of the traditional Chinese medicine Alisma plantago-aquatica, is safe for organisms, and has good clinical application prospects.

The invention relates to the technical field of biological medicines, and particularly discloses application of betaine in preparation of a medicine for preventing or treating sepsis myocardial injury. Betaine (BET) provided by the invention can be used for effectively relieving cytokine storm caused by sepsis injury and inhibiting reduction of core body temperature of a mouse; the abnormal blood routine and blood biochemical indexes are improved. In addition, betaine can reduce generation of active oxygen in myocardial cells of the HL-1 mouse and improve mitochondrial membrane potential imbalance of the myocardial cells of the HL-1 mouse. The chemical structural formula of the betaine is shown in the specification.

The invention relates to application of NMRK2 in regulating and improving myocardial ischemia reperfusion injury, and belongs to the technical field of biological medicine. Based on the lack of medicines for effectively preventing and treating myocardial ischemia-reperfusion injury at present, the invention develops a protection method based on NMRK2 signal regulation and control, specifically, a preparation for enhancing NMRK2 expression or activity is adopted to prepare the medicines for preventing or treating myocardial ischemia-reperfusion injury, and the medicines can systematically enhance the anti-oxidation defense capability of myocardial cells, so that the anti-oxidation defense capability of myocardial cells is enhanced. The tissue injury caused by reperfusion is improved, so that the myocardial ischemia reperfusion injury is effectively prevented and treated. Furthermore, it is found that the NMRK2 can inhibit excessive activation of MST1 / p-MST1 in a Hippo pathway and promote YAP nuclear translocation, so that NADK expression is up-regulated, a Trx1 antioxidant system is enhanced, and a new 'NMRK2-YAP-NADK-Trx1 antioxidant signal pathway' is formed.

The invention belongs to the technical field of medical information processing, and particularly discloses a regression model establishment method and system for detecting related indexes of myocardial cells of Wuzhishan pigs by using blood biochemical indexes, and the method comprises the following steps: collecting blood and heart tissue samples of the Wuzhishan pigs at different month ages, detecting the blood biochemical indexes including liver function, blood fat and blood sugar indexes, and establishing a regression model for detecting the related indexes of myocardial cells of the Wuzhishan pigs. Related indexes of myocardial cells; analyzing the index expression quantity difference, and screening significant difference indexes; then calculating the correlation between the remarkably different blood biochemical indexes and myocardial cell related indexes, and determining high-correlation blood biochemical indexes; and finally, constructing a first version of multiple regression model by respectively taking the myocardial enzyme index and the myocardial cell related index as dependent variables and the high-correlation blood biochemical index as an independent variable, removing outliers and updating the sample set on the basis of the first version of multiple regression model, and constructing a second version of multiple regression model by utilizing the new sample set, and on the basis of the second version of multiple regression model, constructing a third version of multiple regression model by adopting a stepwise regression method. According to the method, related indexes of myocardial cells can be accurately deduced through blood biochemical indexes, and support is provided for Wuzhishan pig heart disease research and model animal research and development.

The invention aims to provide a novel myocardial regeneration induction method. The above-mentioned problem is solved by providing a myocardial regeneration induction method comprising administering a therapeutically effective amount of FOXO6 to myocardial cells or inducing the expression of FOXO6 in myocardial cells.

The application belongs to the technical field of biological medicine, and discloses application of targeted inhibition of TRIM47 in preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury. By establishing a mouse myocardial ischemia-reperfusion injury model, it is found that, compared with a model group, specific knockout of the TRIM47 gene in the heart can significantly improve the heart function of a myocardial ischemia-reperfusion injury mouse, reduce the infarct area after myocardial reperfusion, and also reduce the hypertrophy of myocardial cells and matrix deposition of the mouse, and improve myocardial remodeling. Based on the above findings, TRIM47 can be used as an action target of a myocardial ischemia-reperfusion injury treatment drug, and an inhibitor thereof can be used for preparing a drug for preventing or treating myocardial ischemia-reperfusion injury.

The invention discloses a PH response type modified polydopamine nano preparation loaded with icariin and application of the PH response type modified polydopamine nano preparation in myocardial ischemia resistance, and belongs to the technical field of biological medicine. The nano preparation takes polydopamine (PDA) as a carrier core, the carrier core is modified by methoxy polyethylene glycol (mPEG) and then loaded with icariin (ICA), and the nano preparation is named as mPEG-PDA (at) ICANPs; the preparation process comprises the steps of synthesis of mPEG-OTs, synthesis of mPEG-EDA, synthesis of PDA, preparation of mPEG-PDANPs and preparation of mPEG-PDA (at) ICANPs, under the optimal condition, the particle size of the preparation is 179.6 + / -0.432 nm, PDI is 0.130 + / -0.004, the Zeta potential is 23.4 + / -0.436 mV, the stability is good after the preparation is stored in a dark place at 4 DEG C for 30 days, the ICA drug loading capacity is 14.6 + / -1.08%, the encapsulation efficiency is 64.37 + / -2.31%, and the drug cumulative release rate reaches 73.31 + / -1.64% (pH response drug release) in an environment with the pH value of 6.5 for 72 hours. An in-vitro H9c2 cell OGD model experiment proves that the preparation can remarkably improve the survival rate of ischemic myocardial cells, inhibit apoptosis and reduce LDH release, and the effect of the preparation is superior to that of free ICA. The invention provides an efficient targeting drug delivery system for resisting myocardial ischemia, and has important clinical application value.

The invention belongs to the technical field of biological medicine, and particularly provides application of flufenidone in preparation of a medicine for preventing or treating left heart failure. The research finds that the flufenidone has the effects of relieving myocardial cell hypertrophy under a heart failure cell model and relieving myocardial hypertrophy, fibrosis and heart function deterioration of an aortic constriction animal model. According to the present invention, further research results show that fluorofenidone is directly combined with SERCA2a through Q758, D812 and E917 residues of SERCA2a so as to inhibit recognition, combination and polyubiquitination effects of WWP1 on SERCA2a, such that the protein level and the activity of SERCA2a are stabilized so as to achieve the chronic left heart failure treatment purpose. Therefore, the flufenidone serving as an active ingredient has good application prospect and application value in research and development of novel medicines for treating chronic left heart failure.

The invention relates to a method for producing an animal model of heart failure. The method comprises the step of weakening or deleting DDB1 protein function in myocardial cells of the animal model. The present application demonstrates that nuclear DDB1 co-agglomerates with MEF2C to control NAD + biosynthesis as well as ion homeostasis genes in the heart, and the lack of which results in the development of HFpEF. Development of HFpEF in a'double strike 'mouse model can be reversed through AAV-mediated DDB1 overexpression in myocardial cell nucleuses. Therefore, it is detected that DDB1 coordinates NAD + biosynthesis and ion homeostasis to protect the heart from being affected by ejection fraction retention heart failure caused by obesity, and the scheme of the application has therapeutic significance on treatment of obesity / diabetes HFpEF.

The application relates to the field of myocardial ischemia-reperfusion injury drugs, and discloses application of Gualou Xiebai Baijiu decoction in preparation of myocardial ischemia-reperfusion injury drugs. The myocardial ischemia-reperfusion injury drugs inhibit the GSK-3beta / Drp1-mediated mitochondrial fission pathway by targeting Akt protein, maintain the dynamic balance of mitochondrial dynamics, and play a myocardial protection role. The drugs can promote Akt phosphorylation activation, inhibit GSK-3beta activity, down-regulate Drp1 protein Ser616 site phosphorylation, up-regulate Ser637 site phosphorylation, reduce Drp1 translocation and aggregation to the outer membrane of mitochondria, and simultaneously up-regulate the expression of mitochondrial fusion proteins Mfn1 and Mfn2. The drugs can maintain the structural integrity of mitochondria, improve the mitochondrial membrane potential and ATP content, improve myocardial cell energy metabolism, regulate the expression of apoptosis-related proteins to inhibit myocardial cell apoptosis, improve the cardiac systolic function after ischemia-reperfusion, reduce the myocardial infarction area, reduce the serum myocardial injury marker level, and regulate the oxidative stress state.

The application relates to the technical field of biological medicine, and discloses a drug composition containing nuclear autoantigen sperm protein for promoting myocardial regeneration and repair and application, which comprises an NASP gene; the nucleotide sequence of the NASP gene is shown as SEQ ID NO:1, and the amino acid sequence encoded by the NASP gene is shown as SEQ ID NO:2. The drug composition can promote the number of myocardial cells, repair the necrotic myocardium, and thus improve acute myocardial infarction at the gene level.

The method comprises the following steps: taking red ginseng, radix ophiopogonis and schisandra chinensis, carrying out water extraction and freeze drying to obtain freeze-dried powder, taking the freeze-dried powder, adding distilled water to dissolve the freeze-dried powder, adding the dissolved freeze-dried powder to a macroporous adsorption resin column, carrying out gradient elution with water, a 20% ethanol aqueous solution, a 50% ethanol aqueous solution and a 75% ethanol aqueous solution in sequence, and carrying out vacuum concentration to obtain the effective part of the pulse-activating decoction. From the beginning of sample loading, collecting every 300mL of effluent as a fraction, and collecting the fractions Fr1-Fr16; the chromatographic characteristics are analyzed, fractions with the same chromatographic characteristics are combined, the fractions Fr15-Fr16 are combined into a component yf-10, and the component yf-10 is the effective part of the pulse-activating decoction. According to the effective part disclosed by the invention, toxic parts are removed, so that H9c2 cell injury caused by adriamycin can be protected in a more effective, more stable and lower-toxicity manner, and the application of the component yf-10 in preparation of medicines for treating myocardial cell injury is prompted.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The present application relates to a culture method and application of cardiac progenitor cells with myocardial and epicardial dual differentiation potential. Specifically, the present application provides cardiac progenitor cells with myocardial and epicardial dual differentiation potential, and provides a culture medium and culture method for inducing human pluripotent stem cells to differentiate into the dual potential cardiac progenitor cells, and further provides a method for differentiating the dual potential cardiac progenitor cells into myocardial cells and / or epicardial cells. The present application provides a new cell model for the development process and principle research of early cardiac lineage, and has a wide application prospect in the field of cell therapy and regenerative medicine related to heart diseases.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.